Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with crohn's disease

American Journal of Gastroenterology

Volumn 111, Issue 4, 2016, Pages 529-540

  Gutiérrez, Ana ^a,b   Zapater, Pedro ^b   Juanola, Oriol ^b   Sempere, Laura ^a   García, Marifé ^c   Laveda, Raquel ^d   Martínez, Antonio ^d   Scharl, Michael ^e   González Navajas, José M ^b   Such, José ^f   Wiest, Reiner ^g   Rogler, Gerhard ^e   Francés, Rubén ^b,h  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f HEART AND VASCULAR INSTITUTE   (United Arab Emirates)

^g UNIVERSITY OF BERN   (Switzerland)

^h MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BACTERIAL DNA; CALGRANULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; GENOMIC DNA; INFLIXIMAB; MESALAZINE; METHOTREXATE; RNA 16S; STEROID; BIOLOGICAL MARKER; CYTOKINE; NOD2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BACTERIAL GENE; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; FEMALE; FOLLOW UP; GENE TRANSLOCATION; GENETIC VARIATION; GENOTYPE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; STEROID THERAPY; BACTERIAL TRANSLOCATION; BLOOD; CLINICAL TRIAL; GASTROINTESTINAL ENDOSCOPY; GENETICS; MICROBIOLOGY; SPAIN;

ADULT; BACTERIAL TRANSLOCATION; BIOMARKERS; CROHN DISEASE; CYTOKINES; DNA, BACTERIAL; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GENOTYPE; HUMANS; MALE; NOD2 SIGNALING ADAPTOR PROTEIN; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SPAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959103582     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.8     Document Type: Article

References (52)

1. Gutierrez A, Frances R, Amoros A, et al. Cytokine association with bacterial DNA in serum of patients with Inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 508-14
2. Gutierrez A, Holler E, Zapater P, et al. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is aff ected by NOD2/CARD15 genotype. Inflamm Bowel Dis 2011; 17: 1641-50
3. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of Inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005; 206: 260-76
4. Obermeier F, Dunger N, Strauch UG, et al. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal Inflammation. Gastroenterology 2005; 129: 913-27
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29
6. Sartor RB. Pathogenesis and immune mechanisms of chronic Inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 5S-11
7. Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in Inflammatory bowel disease. Gastroenterology 2011; 140: 1729-37
8. Gutierrez A, Scharl M, Sempere L, et al. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut 2014; 63: 272-80
9. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98: 9237-42
10. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5
11. Chuang TH, Lee J, Kline L, et al. Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol 2002; 71: 538-44
12. Wagner H. Toll meets bacterial CpG-DNA. Immunity 2001; 14: 499-502
13. Chace JH, Hooker NA, Mildenstein KL, et al. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 1997; 84: 185-93
14. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9
15. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-83
16. Krieg AM. CpG motifs in bacterial DNA and their immune Effects. Annu Rev Immunol 2002; 20: 709-60
17. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-61
18. Ligumsky M, Simon PL, Karmeli F, et al. Role of interleukin 1 in Inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 686-9
19. MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-Alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81: 301-5
20. Reinecker HC, Steff en M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-Alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81
21. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6
22. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603
23. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with Inflammatory bowel disease. Am J Hum Genet 2002; 70: 845-57
24. Bonen DK, Cho JH. The genetics of Inflammatory bowel disease. Gastroenterology 2003; 124: 521-36
25. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-4
26. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009; 106: 15813-8
27. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for fi rst surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242: 693-700
28. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359: 1661-5
29. Cosnes J, Cattan S, Blain A, et al. Long-Term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50
30. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal Inflammation. Gastroenterology 2004; 126: 1518-32
31. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classifi cation of Inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A): 5-36
32. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and effi cacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30
33. Such J, Frances R, Munoz C, et al. Detection and identifi cation of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-41
34. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6
35. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther 1999; 13: 1403-11
36. Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with nonadherence to oral medication for Inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525-39
37. Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger Inflammatory bowel disease flares. World J Gastroenterol 2014; 20: 4329-34
38. Vidal A, Gomez-Gil E, Sans M, et al. Life events and Inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol 2006; 101: 775-81
39. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002
40. Feagins LA, Cryer BL. Do non-steroidal anti-Inflammatory drugs cause exacerbations of Inflammatory bowel disease?. Dig Dis Sci 2010; 55: 226-32
41. Torok HP, Glas J, Endres I, et al. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009; 104: 1723-33
42. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifi es a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207-11
43. Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004; 10: 521-8
44. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004; 135: 490-6
45. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with Infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42
46. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in Inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22
47. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8. quiz e10-1
48. Bringiotti R, Ierardi E, Lovero R, et al. Intestinal microbiota: The explosive mixture at the origin of Inflammatory bowel disease?. World J Gastrointest Pathophysiol 2014; 5: 550-9
49. Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn's disease: step-up or top-down?. Expert Rev Gastroenterol Hepatol 2010; 4: 167-80
50. D?Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7: 86-92
51. D?Haens GR, Sartor RB, Silverberg MS, et al. Future directions in Inflammatory bowel disease management. J Crohns Colitis 2014; 8: 726-34
52. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484-91